316 related articles for article (PubMed ID: 27902444)
21. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system.
Zhu H; Dong H; Eksioglu E; Hemming A; Cao M; Crawford JM; Nelson DR; Liu C
Gastroenterology; 2007 Nov; 133(5):1649-59. PubMed ID: 17983809
[TBL] [Abstract][Full Text] [Related]
22. Mesenchymal Stem Cell-Mediated Delivery of an Oncolytic Adenovirus Enhances Antitumor Efficacy in Hepatocellular Carcinoma.
Yoon AR; Hong J; Li Y; Shin HC; Lee H; Kim HS; Yun CO
Cancer Res; 2019 Sep; 79(17):4503-4514. PubMed ID: 31289131
[TBL] [Abstract][Full Text] [Related]
23. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
Plumlee CR; Lazaro CA; Fausto N; Polyak SJ
Virol J; 2005 Dec; 2():89. PubMed ID: 16324217
[TBL] [Abstract][Full Text] [Related]
24. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
[TBL] [Abstract][Full Text] [Related]
25. Identification of Cholesterol 25-Hydroxylase as a Novel Host Restriction Factor and a Part of the Primary Innate Immune Responses against Hepatitis C Virus Infection.
Xiang Y; Tang JJ; Tao W; Cao X; Song BL; Zhong J
J Virol; 2015 Jul; 89(13):6805-16. PubMed ID: 25903345
[TBL] [Abstract][Full Text] [Related]
26. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth.
Ong HT; Federspiel MJ; Guo CM; Ooi LL; Russell SJ; Peng KW; Hui KM
J Hepatol; 2013 Nov; 59(5):999-1006. PubMed ID: 23867315
[TBL] [Abstract][Full Text] [Related]
27. Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo.
El-Sherbiny YM; Holmes TD; Wetherill LF; Black EV; Wilson EB; Phillips SL; Scott GB; Adair RA; Dave R; Scott KJ; Morgan RS; Coffey M; Toogood GJ; Melcher AA; Cook GP
Clin Exp Immunol; 2015 Apr; 180(1):98-107. PubMed ID: 25469725
[TBL] [Abstract][Full Text] [Related]
28. Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
Lawson KA; Mostafa AA; Shi ZQ; Spurrell J; Chen W; Kawakami J; Gratton K; Thakur S; Morris DG
Clin Cancer Res; 2016 Dec; 22(23):5839-5850. PubMed ID: 27220962
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic therapy with vaccinia virus carrying IL-24 for hepatocellular carcinoma.
Deng L; Yang X; Ding Y; Fan J; Peng Y; Xu D; Huang B; Hu Z
Virol J; 2022 Mar; 19(1):44. PubMed ID: 35292065
[TBL] [Abstract][Full Text] [Related]
30. The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro.
Alain T; Kim M; Johnston RN; Urbanski S; Kossakowska AE; Forsyth PA; Lee PW
Br J Cancer; 2006 Oct; 95(8):1020-7. PubMed ID: 17047650
[TBL] [Abstract][Full Text] [Related]
31.
Li G; Cheng J; Mei S; Wu T; Ye T
Mar Drugs; 2018 Jun; 16(6):. PubMed ID: 29880736
[TBL] [Abstract][Full Text] [Related]
32. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
[TBL] [Abstract][Full Text] [Related]
33. Combination Immunotherapy of Oncolytic Flu-Vectored Virus and Programmed Cell Death 1 Blockade Enhances Antitumor Activity in Hepatocellular Carcinoma.
Yu H; Sun F; Xu Y; Yang H; Tian C; Li C; Kang Y; Hao L; Yang P
Hum Gene Ther; 2024 Mar; 35(5-6):177-191. PubMed ID: 38386514
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic Activity of a Novel Influenza A Virus Carrying Granulocyte-Macrophage Colony-Stimulating Factor in Hepatocellular Carcinoma.
Penghui Y; Fang S; Ruilan W; Guanglin L; Hongjing G; Yueqiang D; Zhongpeng Z; Xiaolan Y; Zhaohai W; Shaogeng Z; Xiliang W
Hum Gene Ther; 2019 Mar; 30(3):330-338. PubMed ID: 30205709
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
Ilett EJ; Prestwich RJ; Kottke T; Errington F; Thompson JM; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Vile RG; Melcher AA
Gene Ther; 2009 May; 16(5):689-99. PubMed ID: 19282847
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic gene therapy with recombinant vaccinia strain GLV-2b372 efficiently kills hepatocellular carcinoma.
Ady JW; Johnsen C; Mojica K; Heffner J; Love D; Pugalenthi A; Belin LJ; Chen NG; Yu YA; Szalay AA; Fong Y
Surgery; 2015 Aug; 158(2):331-8. PubMed ID: 26049609
[TBL] [Abstract][Full Text] [Related]
37. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K
Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578
[TBL] [Abstract][Full Text] [Related]
38. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.
Nguyên TL; Abdelbary H; Arguello M; Breitbach C; Leveille S; Diallo JS; Yasmeen A; Bismar TA; Kirn D; Falls T; Snoulten VE; Vanderhyden BC; Werier J; Atkins H; Vähä-Koskela MJ; Stojdl DF; Bell JC; Hiscott J
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14981-6. PubMed ID: 18815361
[TBL] [Abstract][Full Text] [Related]
39. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.
Ben Yebdri F; Van Grevenynghe J; Tang VA; Goulet ML; Wu JH; Stojdl DF; Hiscott J; Lin R
Mol Ther; 2013 Nov; 21(11):2043-53. PubMed ID: 23985699
[TBL] [Abstract][Full Text] [Related]
40. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
